NEXAVAR

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug NEXAVAR contains one active pharmaceutical ingredient (API):

1	Sorafenib UNII 5T62Q3B36J - SORAFENIB TOSYLATE
	Sorafenib is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-β).
	Read more about Sorafenib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NEXAVAR Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX02	Sorafenib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10226F, 10242C, 9380Q
BR	Câmara de Regulação do Mercado de Medicamentos	538912050012113
CA	Health Products and Food Branch	02284227
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29779-05-11
EE	Ravimiamet	1249938
ES	Centro de información online de medicamentos de la AEMPS	06342001, 06342001IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	163494
FR	Base de données publique des médicaments	64463662
GB	Medicines & Healthcare Products Regulatory Agency	106852, 392454
HK	Department of Health Drug Office	55409
IE	Health Products Regulatory Authority	88133, 89012
IL	מִשְׂרַד הַבְּרִיאוּת	6135
IT	Agenzia del Farmaco	037154010
JP	医薬品医療機器総合機構	4291017F1025
LT	Valstybinė vaistų kontrolės tarnyba	1029584, 1090758
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	082M2006
NL	Z-Index G-Standaard, PRK	81450
NZ	Medicines and Medical Devices Safety Authority	12471
PL	Rejestru Produktów Leczniczych	100134312
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63886001
SG	Health Sciences Authority	13339P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546090044
US	FDA, National Drug Code	50419-488
ZA	Health Products Regulatory Authority	A40/26/0776